Fundraising Fox
🦊/People
Sign in

Perry Nisen

Investor

Executive Advisor, Private Equity at Sofinnova Ventures · Board director at Quanta Therapeutics

San Diego, California

Writes $100K – $5M checks · typically $1.5M

Find your path to Perry

332 people in our graph share verified history with Perry — schools, employers, funds. One of them is your warm intro.

Sam BlackmanunlockedPerry: together at GlaxoSmithKline (2010–2012)
×4Perry: together at Stanford University
×4Perry: together at GlaxoSmithKline
×3Perry: together at UT Southwestern Medical Center

About

Perry Nisen is a physician scientist with experience in drug discovery and development, focusing on pre-clinical and clinical companies in oncology, neuroscience, and immunology/inflammation. He joined Sofinnova in 2018 and previously served as CEO of the Sanford Burnham Prebys Medical Discovery Institute and held senior roles at GlaxoSmithKline, including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head, as well as a cancer research leadership role at Abbott Laboratories. He earned a BS from Stanford University and an MD/PhD from the Albert Einstein College of Medicine.

Contact· self-published, not guessed

Invests in

Biotech

Board director at Quanta Therapeutics

Intro paths

→

In turn, Perry can intro founders to Quanta Therapeutics's investors below.

Quanta Therapeutics's investors · 5

Biotechnology Value FundSan Francisco · since 2023Frazier Life SciencesPalo Alto · since 2023Longitude CapitalMenlo Park · $10M – $30M checks · since 2023Sofinnova VenturesMenlo Park · $100K – $15M checks · since 2026Vida VenturesLos Angeles · since 2023

Experience

  1. Quanta TherapeuticsChief Executive Officercurrent2021 — presentSan Francisco and Malvern, PA
  2. Sofinnova InvestmentsExecutive Partner/Advisorcurrent2018 — presentSan Diego County, California, United States
  3. Teva PharmaceuticalsIndependent Director, Chair of Science and Technologycurrent2017 — present
  4. Sanford Burnham Prebys Medical Discovery InstituteChief Executive Officer, Donald Bren Chief Executive Chair2014 — 2017La Jolla, California and Lake Nona, Florida
  5. GlaxoSmithKlineSVP Science and Innovation2012 — 2014
  6. GlaxoSmithKlineInterim Chief Medical Officer2012Greater Philadelphia
  7. GlaxoSmithKlineSenior Vice President and Therapeutic Area Head, Oncology Research and Development2010 — 2012Collegeville, PA
  8. GlaxoSmithKlineSVP Cancer Research2008 — 2010
  9. GlaxoSmithKlineSVP Clinical Pharmacology and Discovery Medicine2004 — 2008
  10. AbbottDivision VP Global Oncology Development2001 — 2004
  11. AbbottDivision VP Cancer Research1997 — 2001
  12. UT Southwestern Medical CenterProfessor1997
  13. UT Southwestern Medical CenterAssociate Professor1992 — 1997
  14. UT Southwestern Medical CenterMember, Genetics and Development Graduate Training Program1989 — 1997
  15. UT Southwestern Medical CenterAssistant Professor1989 — 1992

Skills & more

Oncology47Clinical Development27Drug Development35Biotechnology26Clinical Trials15Lifesciences1Drug Discovery14Immunology7Regulatory Affairs2Biopharmaceuticals6Clinical Research6Life Sciences33
+6 moreMedicineVaccinesInfectious DiseasesR&DResearch and Development (R&D)Pharmaceutical Industry

From Perry's professional profile.

Investments

Board seats

Quanta

Investor

XyloCor Therapeutics

Sources: the firm's website · curated public sources.

Colleagues at Sofinnova Ventures

Alex Chan
Controller, Private Equity at Sofinnova Ventures
Alex Dulnev
IT Manager at Sofinnova Ventures
Amanda Phillips
Executive Assistant at Sofinnova Ventures
Anastasia Voevodin
Analyst, Public Equity at Sofinnova Ventures
Aneal Tenjarla
Partner, Associate Portfolio Manager, Public Equity at Sofinnova Ventures
Calvin Sternick
Analyst, Public Equity at Sofinnova Ventures
Chris Carpenter
Executive Partner, Private Equity at Sofinnova Ventures
David Kabakoff
Executive Partner, Private Equity at Sofinnova Ventures

Frequently asked questions

Who is Perry Nisen?
Perry Nisen is a physician scientist with experience in drug discovery and development, focusing on pre-clinical and clinical companies in oncology, neuroscience, and immunology/inflammation. He joined Sofinnova in 2018 and previously served as CEO of the Sanford Burnham Prebys Medical Discovery Institute and held senior roles at GlaxoSmithKline, including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head, as well as a cancer research leadership role at Abbott Laboratories. He earned a BS from Stanford University and an MD/PhD from the Albert Einstein College of Medicine.
Where does Perry Nisen work?
Perry Nisen is Executive Advisor, Private Equity at Sofinnova Ventures and Board director at Quanta Therapeutics.
What does Perry Nisen invest in?
Perry Nisen invests in Biotech.
What check size does Perry Nisen write?
Perry Nisen typically writes checks of $100K – $5M.
What boards does Perry Nisen sit on?
Perry Nisen holds tracked board seats at Quanta.
What companies has Perry Nisen invested in?
Investments tracked here include XyloCor Therapeutics.
Where did Perry Nisen go to school?
Perry Nisen studied at Albert Einstein College of Medicine (MD, PhD); Stanford University (Bachelor's degree, Medical Microbiology).

Founder mafias

Sofinnova Ventures mafia2

Also came through, then founded or led a company.

Greg MondrePartner and CFOFounded Silver Lake

Same school

Shared employers